Table 1

Association analysis of four tag SNPs and haplotypes with SLE in the stage I study

No.

SNP

Controls

Cases

Crude OR (95% CI)

Crude P

Adjusted OR (95% CI)

Adjusted P

rs2031920

allelic

C

462

401

1.081 (0.804 to 1.454)

0.604

1.029 (0.887 to 1.195)

0.703

T

114

107

geonotypic

C/C+C/T

184 + 94

159 + 83

1.379 (0.585 to 3.247)

0.461

1.151 (0.749 to 0.176)

0.52

T/T

10

12

rs2070672

allelic

A

480

430

0.907 (0.655 to 1.256)

0.557

0.968 (0.821 to 1.142)

0.701

G

96

78

geonotypic

A/A+G/G

199 + 7

186 + 10

0.743 (0.504 to 1.096)

0.135

0.753 (0.508 to 1.115)

0.156

A/G

82

58

rs8192772

allelic

T

454

426

0.913 (0.681 to 1.224)

0.542

0.970 (0.837 to 1.125)

0.686

C

122

102

geonotypic

T/T + T/C

171 + 112

174 + 76

3.170 (1.126 to 8.925)

0.022

1.912 (1.131 to 3.234)

0.016

C/C

5

14

rs2480256

allelic

G

360

295

1.282 (1.007 to 1.633)

0.043

1.128 (0.999 to 1.274)

0.053

A

216

223

geonotypic

G/G+G/A

106 + 148

93 + 109

2.182 (1.377 to 3.459)

0.001

1.475 (1.170 to 1.860)

0.001

A/A

34

59

Haplotype (rs2031920-rs2070672-rs8192772-rs2480256)

Frequency in the Control

Frequency in the SLE

OR (95% CI)

P-value

CATG

58.50%

54.70%

0.856 (0.674 to 1.088)

0.205

TATA

15.70%

19.70%

1.321 (0.967 to 1.803)

0.081

CGCA

15.90%

14.50%

0.896 (0.644 to 1.247)

0.513

Combination of rare haplotypes (frequency <5%)

9.90%

11.10%

CI, confidence interval; OR, odds ratio; SLE, systemic lupus erythematosis; SNP, single nucleotide polymorphism.

Liao et al. Arthritis Research & Therapy 2011 13:R11   doi:10.1186/ar3232